Drugs in Dev. Ophthalmology
Phase IV
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eyenovia Provides Update on Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
Details : Mydcombi is FDA approved, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).
Product Name : Mydcombi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2024
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alimera Completes Recruitment for the Synchronicity Study
Details : YUTIQ (fluocinolone acetonide) intravitreal implant 0.18mg is being evaluated in phase 4 clinical trials for the treatment of chronic non-infectious uveitis and related intraocular inflammation.
Product Name : Iluvien
Product Type : Steroid
Upfront Cash : Inapplicable
April 01, 2024
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cequa (cyclosporine ophthalmic solution) is a patented, novel, proprietary nanomicellar NCELL formulation of cyclosporine in a clear, preservative-free, aqueous solution. It is indicated to increase tear production in patients with keratoconjunctivitis s...
Product Name : Cequa
Product Type : Peptide
Upfront Cash : Inapplicable
December 10, 2023
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Ocular Therapeutix
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dextenza (dexamethasone), a corticosteroid intracanalicular insert, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.
Product Name : Dextenza
Product Type : Steroid
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Ocular Therapeutix
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Iluvien (fluocinolone acetonide intravitreal implant), is designed to release sub-microgram levels, a corticosteroid, for 36 months, to reduce recurrence of disease and number of treatments required, enabling patients to maintain vision longer with fewer...
Product Name : Iluvien
Product Type : Steroid
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments
Details : PALADIN phase 4 data demonstrate ILUVIEN (fluocinolone acetonide) patients experienced on average an increase in visual acuity, a significant decrease in retinal thickness and a predictable and manageable safety profile over 36 months.
Product Name : Iluvien
Product Type : Steroid
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 4 PALADIN Study with ILUVIEN® Published in Peer-Reviewed Journal Ophthalmology
Details : ILUVIEN (fluocinolone acetonide), sustained release intravitreal implant, demonstrated statistically significant improvements in best-corrected visual acuity, central subfield thickness, also resulted in a 70.5% reduction in treatment burden at 36 months...
Product Name : Iluvien
Product Type : Steroid
Upfront Cash : Inapplicable
February 23, 2022
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The real-world data from the Phase 4 PALADIN study show that patients receiving one or less total injections per year for their DME after the ILUVIEN injection increased three-fold from prior to the ILUVIEN injection.
Product Name : Iluvien
Product Type : Steroid
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Idebenone
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Santhera's Raxone® Meets Phase 4 Endpoint in Optic Neuropathy
Details : Raxone (idebenone) is an antioxidant benzoquinone, small molecule drug candidate which is indicated for the treatment of Leber’s Hereditary Optic Neuropathy.
Product Name : Raxone
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2021
Lead Product(s) : Idebenone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The clinical trial is designed to demonstrate the clinical efficacy and safety of LO2A in DES patients with Sjögren's syndrome. Phase IV study aims at expanding LO2A's current approved status.
Product Name : LO2A
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 05, 2020
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
